FDA approves new COVID-19 vaccines for seniors

Published Updated



The Food and Drug Administration on Thursday approved COVID-19 vaccines for the 2026-27 season for people at higher risk of severe illness, including everyone 65 and older and younger people with certain underlying health conditions.

The FDA approved Moderna’s vaccine for people ages 6 months and older, Pfizer’s for those ages 5 and older, and Sanofi’s for people ages 12 and older. The agency also approved a lower-dose Moderna vaccine, mNEXSPIKE, for people ages 12 and up.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.